Small Molecule Drug Discovery Market Report 2026

The small molecule drug discovery market size has grown rapidly in recent years. It will grow from $67.94 billion in 2025 to $75.56 billion in 2026 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to increasing r&d investments by pharmaceutical companies, growth in chronic disease prevalence, advancements in molecular biology techniques, rising demand for cost-effective therapeutics, emergence of contract research organizations (cros).

The small molecule drug discovery market size is expected to see rapid growth in the next few years. It will grow to $117.05 billion in 2030 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to integration of ai and machine learning in drug discovery, expansion of precision medicine initiatives, increasing collaborations between biotech and pharma, adoption of automated high-throughput platforms, growing focus on rare and complex diseases. Major trends in the forecast period include high-throughput screening adoption, combinatorial chemistry advancements, nanotechnology integration in drug design, personalized medicine development, target validation and lead optimization enhancements.

The increasing prevalence of chronic diseases is expected to drive the growth of the small molecule drug discovery market in the future. Chronic diseases are conditions that last for a year or more, hinder daily activities, and require ongoing medical care, or both. Small-molecule medications can be used to treat chronic conditions such as HIV, cancer, infections, heart disease, and renal disease, and they are generally more affordable for patients dealing with these long-term conditions. Consequently, the rising incidence of chronic diseases is anticipated to support the growth of the small molecule drug discovery market. For example, according to a 2023 report by the National Institutes of Health (NIH), a US-based biomedical research agency, the number of individuals aged 50 and older with at least one chronic illness in the United States is expected to reach 142.66 million by 2050. Furthermore, the population with multimorbidity is projected to grow to 14.968 million by 2050. Therefore, the increasing prevalence of chronic diseases is a key driver of the small molecule drug discovery market.

Leading companies in small molecule drug discovery are forming partnerships to boost revenues in the market. These partnerships often encourage innovation by combining the strengths of different organizations. For instance, in November 2023, Evommune, a US-based non-profit organization, and Accutar Biotechnology, a US-based biotechnology company, announced a strategic collaboration focused on AI-driven drug discovery for chronic inflammatory diseases. This partnership aims to use Accutar's proprietary AI platform alongside Evommune's expertise to identify novel small molecule drug candidates.

In April 2025, Johnson & Johnson, a US-based biopharmaceutical company that offers prescription pharmaceuticals, medical devices, and consumer health products, acquired Intra Cellular Therapies, Inc. for an undisclosed sum. This acquisition is intended to strengthen Johnson & Johnson's neuroscience portfolio, expand its small-molecule central nervous system therapeutic capabilities, and accelerate growth in mental health and neurodegenerative disease treatments. Intra Cellular Therapies, Inc. is a US-based biopharmaceutical company focused on developing small-molecule drugs for the central nervous system, including treatments for psychiatric and neurodegenerative disorders.

Major companies operating in the small molecule drug discovery market are Pfizer Inc., GlaxoSmithKline plc, AstraZeneca, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Johnson & Johnson, Gilead Sciences Inc., Merck KGaA, Novartis AG, 4SC AG, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Labcorp Drug Development, ICON Public Limited Company, Charles River Laboratories, Aluda Pharmaceuticals, Corcept Therapeutics, Edison Oncology, Escend Pharmaceuticals, Terray Therapeutics, Apollomics, Astex Pharmaceuticals, Pardes Biosciences, Xynomic Pharmaceuticals, Zevra Therapeutics, UNION therapeutics, Allarity Therapeutics, Cyteir Therapeutics, BigHat Biosciences.

North America was the largest region in the small molecule drug discovery market in 2025. Europe is expected to be the fastest-growing region in the small molecule drug discovery market report during the forecast period. The regions covered in the small molecule drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the small molecule drug discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the small molecule drug discovery market by increasing the cost of importing critical reagents, laboratory equipment, and chemical intermediates, leading to supply chain disruptions. Asia-Pacific regions, particularly China and India, are most affected due to their role in providing raw materials and APIs. Segments such as high-throughput screening and combinatorial chemistry face higher operational costs, while pharmaceutical companies are exploring local sourcing and regional manufacturing to mitigate risks. Positive impacts include encouraging domestic production and boosting local contract research capabilities.

The small molecule drug discovery market research report is one of a series of new reports that provides small molecule drug discovery market statistics, including small molecule drug discovery industry global market size, regional shares, competitors with a small molecule drug discovery market share, detailed small molecule drug discovery market segments, market trends and opportunities, and any further data you may need to thrive in the small molecule drug discovery industry. This small molecule drug discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Small Molecule Drug Discovery is the process of identifying and developing low molecular weight compounds that can interact with specific biological targets to treat diseases. This approach is used to create effective medications capable of modulating biological pathways, ultimately leading to improved therapeutic outcomes.

The primary drug types in small molecule drug discovery include small molecule drugs and biologic drugs. A small-molecule drug is any organic chemical with a molecular weight of less than 900 daltons that can influence a biological process. Various technologies such as high throughput screening, pharmacogenomics, combinatorial chemistry, and nanotechnology are employed across a range of therapeutic areas, including oncology, central nervous system disorders, cardiovascular conditions, respiratory issues, metabolic disorders, and gastrointestinal diseases, among others. The process typically follows several phases, including target identification or validation, hit generation and selection, lead identification, and lead optimization, with pharmaceutical companies, contract research organizations, and other entities involved in these stages.

The small molecule drug discovery market consists of sales of diphenhydramine, aspirin, and other “medicine cabinet” drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.